PGEN

Precigen, Inc. (PGEN) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Precigen, Inc. is a commercial-stage biopharmaceutical company that transitioned from a development-stage entity following the FDA approval of its first commercial product, Papzimeos (zopapogene imadenovec-drba), in August 2025. Papzimeos is the first and only FDA-approved therapy for recurrent respiratory papillomatosis (RRP). The company operates as a single segment, focusing on immuno-oncology, autoimmune disorders, and infectious diseases, with a subsidiary, Exemplar, providing research models.

Key Financial Metrics

Liquidity: As of March 31, 2026, the company held approximately $56.7 million in cash, cash equivalents, and investments. Management believes existing liquid assets and anticipated Papzimeos revenue will fund operations for at least one year.

Material Changes vs. Prior Period

• Revenue Surge: Total revenues increased by over 200% to $23.3 million, driven primarily by $21.6 million in Papzimeos product sales. No Papzimeos revenue was recognized in Q1 2025 as the product was not yet approved.
• Significant Loss Reduction: Net loss improved by 85.4% to $7.9 million. This improvement was largely due to the absence of a $32.5 million non-cash charge related to the change in fair value of warrant liabilities recorded in Q1 2025. Warrant liabilities were reclassified to equity in Q3 2025.
• Expense Shifts:
  • R&D Expenses: Decreased 46.2% to $5.6 million. This reduction is primarily due to the reclassification of Papzimeos manufacturing costs from R&D to Cost of Products and Services following FDA approval.
  • SG&A Expenses: Increased 70.3% to $21.0 million, reflecting the ramp-up of commercialization, marketing, and personnel costs associated with the Papzimeos launch.
• Debt: The company incurred $2.9 million in interest expense related to a $100 million term loan facility entered into in September 2025.

Guidance, Outlook, and Risks

• Commercial Outlook: The company expects the majority of future revenues to derive from Papzimeos sales. Management anticipates selling through pre-launch inventory in 2026, with gross margins expected to stabilize between high 80% and low 90% once pre-launch inventory is depleted.
• Pipeline Status:
  • Papzimeos: Commercial launch ongoing; MAA submitted to EMA and under review.
  • PRGN-2009: Phase 2 trials ongoing for HPV-associated oropharyngeal and cervical cancers.
  • PRGN-3006: Phase 1b enrollment completed for AML; seeking strategic partnerships.
  • Paused Programs: Enrollment paused for PRGN-3005 and PRGN-3007 as part of strategic prioritization.
• Risks: Key risks include the forecasted demand for Papzimeos, payer coverage and reimbursement rates, competition, manufacturing technical risks, and the need for additional capital if revenue growth does not meet cost structures. The company has an accumulated deficit of $2.3 billion.

Investor Verification Checklist

• Papzimeos Sales Velocity: Verify the rate of commercial adoption and payer reimbursement rates to assess if revenue projections are sustainable.
• Cash Burn Rate: Monitor the net cash used in operating activities ($43.8M in Q1) against the $56.7M liquidity position to determine the runway without additional financing.
• Debt Covenants: Confirm continued compliance with the $100M term loan covenants, specifically minimum net sales and liquidity requirements.
• Inventory Valuation: Review the $14.7M inventory balance and the assumptions regarding the net realizable value of pre-launch inventory.
• European Approval: Track the status of the Marketing Authorization Application (MAA) with the EMA for Papzimeos.